Bayer’s $14.2 billion Merck buy shows pharma strategy split

Norbert Hueltenschmidt, a partner at Bain & Company and head of the Healthcare practice in Europe, Africa and the Middle East, comments on the global pharmaceutical industry after Bayer's acquisition of Merck & Co. “This business is not necessarily as profitable as the high-end innovation, for example, on the oncology side,” he said. “What you are seeing is a little bit of a matrix that companies need to manage."